Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
about
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisStandards of medical care in diabetes--2012Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patientsTherapeutic modalities in diabetic nephropathy: standard and emerging approaches.All-cause mortality in patients with type 2 diabetes in association with achieved hemoglobin A(1c), systolic blood pressure, and low-density lipoprotein cholesterol levelsStandards of medical care in diabetes--2013Management of Diabetic Nephropathy in the Elderly: Special Considerations.The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.Diabetes: managing dyslipidaemia.Life expectancy in a large cohort of type 2 diabetes patients treated in primary care (ZODIAC-10)Standards of medical care in diabetes--2010.Management of Elevated Cholesterol in the primary prevention Group of Adult Japanese (MEGA) Study assists the view that a fasting plasma glucose level ≥100 mg/dL increases cardiovascular risk.American Diabetes Association indications for statins in diabetes: is there evidence?Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.Reassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients--a systematic review and meta-analysis.Paradoxical negative HDL cholesterol response to atorvastatin and simvastatin treatment in Chinese type 2 diabetic patientsAre statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in FinlandType 2 diabetes and cardiovascular disease: Have all risk factors the same strength?Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.Standards of medical care in diabetes--2011.Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis.Treatment of dyslipidemia in patients with type 2 diabetes.Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trialTrends in low-density lipoprotein cholesterol goal achievement in high risk United States adults: longitudinal findings from the 1999-2008 National Health and Nutrition Examination Surveys.Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008.Possible association of ABCB1:c.3435T>C polymorphism with high-density-lipoprotein-cholesterol response to statin treatment--a pilot study.Effects of statin medication on mortality risk associated with type 2 diabetes in older persons: the population-based AGES-Reykjavik Study.Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal TransplantationABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysisBaseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies.The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitusLevels of atherogenic lipoproteins are unexpectedly reduced in interstitial fluid from type 2 diabetes patients.Long-term (52-78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients.Lipids for psychiatrists - an overview.Coping with new challenges in acute coronary syndromes.Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.Fibrates after the FIELD study: Some answers, more questions.Metabolic predictors of ischemic heart disease and cerebrovascular attack in elderly diabetic individuals: difference in risk by age.
P2860
Q22241786-DF7F5B4A-6A03-4897-9544-32093E0E6328Q24194514-627034FD-F8CA-4DA1-B8A1-26E5F9A2E027Q24632533-B1F3587C-0ABB-4A53-8D8B-4F9270518AF2Q27003173-905449FC-BA2A-4598-B9C2-41D7B33EE863Q27007027-0488E233-D3D9-455D-8293-A9AEB3736F3FQ28544402-CD32F930-5284-4785-B63C-00953427994DQ29620309-66D6FAF4-A665-4A85-8EA4-A67F41A6A804Q30353386-4EF2C298-AB24-4F10-AFAA-8330486D1FE6Q30380628-E2159A14-5466-4F0A-B214-1AD9B43A78F8Q33446544-446417D1-1E25-4410-9202-70A679AB73A6Q33497934-4F315892-5669-448D-9D4A-12BEF94E099FQ33554238-71B4E12C-F55C-4455-A9DE-2172A32AAC77Q33603564-9CD55259-C47A-4A64-B91B-290907134F55Q33610712-FF2A6661-7B25-467F-9911-14DB874444A5Q33706621-E58193A4-5F40-40A4-A032-6E523E7257BDQ33776194-81C2ADF2-C39D-41DD-B084-A2C82E641B0CQ33776201-83F578DE-3BF2-43B4-81AA-EF0BA44535D4Q33776208-248AA0E1-7826-456B-8C33-CCB254B11C09Q33795544-C772DA15-3A23-4D55-BFEF-4C60215743FCQ34023548-BF9B187D-10D2-4F9F-8D64-887BA1B357A5Q34142678-F34196B9-308B-4DD2-A12D-0ABD6B1A52BBQ34425055-117B7CC9-B0EB-4AE8-A5F7-6655FE255DA6Q34491726-6B783BC2-F45E-4638-803B-3E63FCD37D84Q34499472-095F537D-34E9-481A-ACC5-920FE87CE7C2Q34571157-53D48363-592B-45F0-904E-9A29C53F5306Q34657896-0BF388A8-B0DC-414E-926B-19518C91DFB1Q34994966-40249A10-2447-4C7F-8749-DB02E16E200DQ35099950-809D6B81-A729-450D-91C4-EB9A8BB216FDQ35320148-05BE3E4E-1774-4D26-87B3-77C66539285DQ35675305-77BB2031-C59B-48A5-9365-4F088AAC67BDQ35799847-68AD7290-73A0-4ED1-AABF-750CD0A84886Q35809770-9E970CF5-85AA-41DB-A9C0-BA5EC06B8441Q35871965-771C1849-3631-4F75-9D3A-51DC29BA7AA0Q35886333-04CD12F8-707D-4761-9526-CBF7D68B5CAFQ36092464-4DAECA30-5295-4210-B845-283D3C64741EQ36310307-5BC625E2-DD01-48A5-B7FF-3E6902E8783AQ36575461-9FC2E001-2F1C-4A17-9D85-28E44137E9F0Q36593266-ED89895E-1785-4770-BCA8-434C6EDFBDE6Q36679599-5332597D-C180-4B68-B045-9D86FBD8B6DFQ36687937-54024371-B2B7-4CCF-9FEC-B9A9C02778D8
P2860
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Reduction in cardiovascular ev ...... ipid-lowering arm (ASCOT-LLA).
@ast
Reduction in cardiovascular ev ...... ipid-lowering arm (ASCOT-LLA).
@en
Reduction in cardiovascular ev ...... ipid-lowering arm (ASCOT-LLA).
@nl
type
label
Reduction in cardiovascular ev ...... ipid-lowering arm (ASCOT-LLA).
@ast
Reduction in cardiovascular ev ...... ipid-lowering arm (ASCOT-LLA).
@en
Reduction in cardiovascular ev ...... ipid-lowering arm (ASCOT-LLA).
@nl
prefLabel
Reduction in cardiovascular ev ...... ipid-lowering arm (ASCOT-LLA).
@ast
Reduction in cardiovascular ev ...... ipid-lowering arm (ASCOT-LLA).
@en
Reduction in cardiovascular ev ...... ipid-lowering arm (ASCOT-LLA).
@nl
P2093
P50
P1433
P1476
Reduction in cardiovascular ev ...... ipid-lowering arm (ASCOT-LLA).
@en
P2093
Arni Kristinsson
Eoin O'Brien
Gareth Beevers
Gordon T McInnes
Hans Wedel
Jan Ostergren
Jesper Mehlsen
Markku Nieminen
Neil R Poulter
Peter S Sever
P304
P356
10.2337/DIACARE.28.5.1151
P407
P577
2005-05-01T00:00:00Z